Clinical Trial Update: Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS [Phase 4]

View source ↗

Summary

A Phase 4 randomized trial comparing two FDA-approved therapies for relapsing-remitting multiple sclerosis to assess disease progression was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 4 | Status: TERMINATED